Comparison of high-sensitivity C-reactive protein and fetuin-A levels before and after treatment for subjects with subclinical hyperthyroidism

Bilgir O., Bilgir F., Topcuoglu T., Calan M., Calan Ö.

ENDOCRINE, cilt.45, sa.2, ss.244-248, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 45 Sayı: 2
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1007/s12020-013-9993-z
  • Dergi Adı: ENDOCRINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.244-248
  • Anahtar Kelimeler: sCD40L, High-sensitivity C-reactive protein, Fetuin-A, Subclinical hyperthyroidism, CORONARY-HEART-DISEASE, ALL-CAUSE MORTALITY, THYROID-DYSFUNCTION, BLOOD-PRESSURE, RISK, HORMONE, METAANALYSIS, ASSOCIATION, COMMUNITY
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

This study was designed to show the effect of propylthiouracil treatment on sCD40L, high-sensitivity C-reactive protein, and fetuin-A levels on subjects with subclinical hyperthyroidism. After checking sCD40L, high-sensitivity C-reactive protein, and fetuin-A levels of 35 patients with subclinical hyperthyroidism, each was given 50 mg tablets of propylthiouracil three times daily. After 3 months, sCD40L, high-sensitivity C-reactive protein, and fetuin-A levels were then compared to the levels before treatment. Although high-sensitivity C-reactive protein and sCD40L levels were normal in the subclinical hyperthyroidism patients compared to the healthy controls, fetuin-A levels were statistically significantly higher (*p = 0.022). After treatment, fetuin-A levels of subclinical hyperthyroidism patients decreased statistically significantly compared to the levels before treatment (**p = 0.026). sCD40L and high-sensitivity C-reactive protein levels did not have a statistically significant difference compared to the control group and post-propylthiouracil treatment. In subclinical hyperthyroidism patients, high fetuin-A levels before propylthiouracil treatment and decreases in these levels after treatment in cases with subclinical hyperthyroidism indicated the possibility of preventing long-term cardiac complications with propylthiouracil treatment.